Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone after reperfusion therapy for acute ischemic stroke
IRCT20260701070037N1Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of edaravone in ischemic stroke (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Clinical improvement and Three-month mortality. Started Oct 2026; status: recruiting.
02
Drugs
edaravone
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on IRCT20260701070037N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260701070037N1.